Management and treatment of cardiac ischemia induced by VEGF inhibitors should be tailored to the patient’s cancer severity, life expectancy, comorbidities, and available highly effective antineoplastic alternatives (Lyon et al., 2022). Here, VEGFA is linked to myocardial ischemia.